Blueprint Medicines (BPMC) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Blueprint Medicines (BPMC) PT Raised to $70 at Wedbush
November 1, 2017 7:17 AM EDTWedbush analyst David Nierengarten raised his price target on Blueprint Medicines (NASDAQ: BPMC) to $70.00 (from $66.00) while maintaining a Outperform rating after the company reported enrollment progress across a number of studies of their wholly-owned kinase assets, and reiterated timeline for future trial... More
